Continuation Study for Latozinemab

NCT06111014 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
17
Enrollment
INDUSTRY
Sponsor class

Stopped The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's

Conditions

Interventions

Sponsor

Alector Inc.